PeraMobile and PeraWatch vs Viz HCM
AI Verdict
Choose PeraMobile and PeraWatch if…
Choose PeraMobile and PeraWatch if your organization requires a comprehensive, system-wide solution for real-time patient acuity monitoring and predictive analytics across your entire patient population. This tool is ideal for identifying general patient deterioration sooner, enabling earlier intervention to improve overall quality of care and reduce costs across various clinical scenarios.
View PeraMobile and PeraWatch →Choose Viz HCM if…
Choose Viz HCM if your primary objective is to significantly reduce the time to diagnosis and treatment for suspected Hypertrophic Cardiomyopathy (HCM) through AI-powered ECG analysis. This specialized tool is best suited for health systems focused on optimizing cardiac care coordination and clinical workflows specifically for HCM patients, ensuring rapid identification and referral to appropriate specialists.
View Viz HCM →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | PeraMobile and PeraWatch | Viz HCM |
|---|---|---|
| Pricing | Contact for pricing | Subscription-based |
| Deployment | Software-only, integrated with EHRs, web-based access, mobile application, on user-provided hardware. | Cloud-based platform, integrated into hospital IT systems (EHR, PACS). |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz HCMViz HCM (Tool B) demonstrates superior usability, with 90% of surveyed customers citing ease of use as a top reason for preference due to its simple, streamlined interface for essential information and alerts. While PeraMobile (Tool A) offers mobile access and visual dashboards, external validation points to a more intuitive and user-friendly experience for Viz HCM, which also ranked #1 in 'Ease of Implementation & Adoption' and 'User Satisfaction & Acceptance' in a Black Book survey.
Clinical Value
Viz HCMBoth tools are FDA-cleared and offer significant clinical value. PeraMobile/PeraWatch (Tool A) provides broad patient acuity scoring with the Rothman Index, demonstrating reductions in mortality and readmissions across various patient populations. However, Viz HCM (Tool B) offers highly specialized, AI-powered ECG analysis for Hypertrophic Cardiomyopathy (HCM) detection and care coordination, with extensive real-world evidence showing it significantly reduces diagnosis time for this often underdiagnosed condition. Its targeted and proven impact on a specific, challenging disease gives it a slight edge.
Pricing & Value
Viz HCMViz HCM (Tool B) offers greater transparency in its pricing, being subscription-based, and crucially, explicitly mentions CMS reimbursement availability for specific CPT codes, which directly enhances its value proposition for healthcare providers by offsetting costs. PeraMobile/PeraWatch (Tool A) does not publicly disclose its pricing, making it difficult for potential customers to assess its financial value without direct contact.
Enterprise Readiness
Viz HCMViz HCM (Tool B) explicitly states 'Yes' for both HIPAA compliance and Business Associate Agreements (BAA), and provides a comprehensive Trust Center with documentation for SOC 2 Type II, ISO certificates, and other security and privacy assurances. While PeraMobile/PeraWatch (Tool A) is 'Likely' compliant, Tool B's explicit statements, broader integration capabilities (EHR, PACS), and robust security documentation demonstrate a higher level of enterprise readiness and assurance.
Innovation
Viz HCMWhile both tools leverage predictive analytics, Viz HCM (Tool B) showcases a more cutting-edge and specialized innovation by applying AI to real-time ECG analysis for the detection of Hypertrophic Cardiomyopathy (HCM) and automating care coordination. This specific application created a new FDA regulatory category for cardiovascular machine learning-based notification software. PeraMobile/PeraWatch (Tool A) provides broader patient deterioration prediction, which, while valuable, is a more established application of predictive analytics.
Support & Docs
Viz HCMViz HCM (Tool B) offers comprehensive support, including 24/7/365 urgent phone support, email support, a Help Center, customer resources, user guides, and a dedicated customer success team to aid adoption and track metrics. PeraMobile/PeraWatch (Tool A), supported by Spacelabs Healthcare, also provides 24/7 technical support and product manuals. However, Viz.ai's detailed customer success program and educational resources like Viz Academy suggest a more structured and proactive approach to customer support and education.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | PeraMobile and PeraWatch | Viz HCM |
|---|---|---|
| Company | PeraHealth (acquired by Spacelabs Healthcare) | Viz.ai |
| Primary Use Case | Predictive analytics solutions to help healthcare providers identify at-risk patients sooner for earlier intervention, improve quality, and reduce costs. | FDA-cleared AI tool that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and coordinate cardiac care, significantly reducing diagnosis time. |
| Key Technology/Methodology | Predictive analytics powered by the FDA-cleared Rothman Index. | AI-powered ECG analysis for Hypertrophic Cardiomyopathy (HCM) detection. |
| Specific Clinical Focus | Real-time patient acuity scoring and predictive analytics for patient deterioration. | Hypertrophic Cardiomyopathy (HCM) detection and cardiac care coordination. |
| Mobile Access | Mobile access for on-the-go clinicians (PeraMobile). | Mobile-based alerts and notifications to multidisciplinary care teams. |
Videos
Demos, reviews, and walkthroughs featuring PeraMobile and PeraWatch and Viz HCM.